Name | L-Norleucine |
Synonyms | H-Nle-OH L-Norleucine Glycoleucine L-nor-Leucine (S)-Norleucine n-C4H9CH(NH2)COOH Norleucine Solution Norleucine, L- (8CI) Alpha-Aminocaproic Acid alpha-aminocaproic acid Hexanoic acid, 2-amino-, (S)- |
CAS | 327-57-1 |
EINECS | 206-321-4 |
InChI | InChI=1/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1 |
Molecular Formula | C6H13NO2 |
Molar Mass | 131.17 |
Density | 1.1720 (estimate) |
Melting Point | >300 °C (lit.) |
Boling Point | 234.0±23.0 °C(Predicted) |
Specific Rotation(α) | 22 º (c=2, 6N HCl) |
Flash Point | 275 °C |
Water Solubility | 1.6 g/100 mL (23 ºC) |
Solubility | 1.6 g/100 mL (23°C) |
Vapor Presure | 0.0188mmHg at 25°C |
Appearance | Crystalline Powder |
Color | White to off-white |
Merck | 14,6706 |
BRN | 1721750 |
pKa | 2.335(at 25℃) |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 23 ° (C=5, 5mol/L HC |
MDL | MFCD00064423 |
In vitro study | L-Norleucine is an isomer of leucine, specifically affecting protein synthesis in skeletal muscle. L-Norleucine has antiviral activity. L-Norleucine interacts with hnRNPA2/B1 protein to suppresses the expressions of Twist1 and Snail, two inhibitors of E-cadherin, and promotes the expression of E-cadherin, resulting in the inhibition of tumor metastasis. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 43 - May cause sensitization by skin contact |
Safety Description | S36/37 - Wear suitable protective clothing and gloves. S24/25 - Avoid contact with skin and eyes. S22 - Do not breathe dust. |
WGK Germany | 3 |
RTECS | RC6308000 |
TSCA | Yes |
HS Code | 29224995 |
Reference Show more | 1. [IF=3.765] Xia Xiaojing et al."Preparation and evaluation of a novel solid dispersion using leucine as carrier."J Pharm Pharmacol. 2020 Jan;72(2):175-184 |